scholarly journals PND88 FACTORS INFLUENCING PATIENTS' WILLINGNESS TO PAY FOR DISEASE-MODIFYING THERAPIES FOR MULTIPLE SCLEROSIS

2020 ◽  
Vol 23 ◽  
pp. S276
Author(s):  
N. Poudel ◽  
S. Ngorsuraches
Keyword(s):  
Multiple Sclerosis ◽  
Willingness To Pay ◽  
Factors Influencing ◽  
Disease Modifying Therapies ◽  
Disease Modifying

Multiple sclerosis and disease modifying therapies: results of two UK surveys on factors influencing choice

2015 ◽  
Vol 11 (1) ◽  
pp. 7-13 ◽  
Author(s):  
Samantha Colhoun ◽  
Carmel Wilkinson ◽  
Alan Izat ◽  
Sarah White ◽  
Emily Pull ◽  
...  
Keyword(s):  
Multiple Sclerosis ◽  
Factors Influencing ◽  
Disease Modifying Therapies ◽  
Disease Modifying

scholarly journals Ethical use of off-label disease-modifying therapies for multiple sclerosis

2021 ◽  
pp. 135245852110302
Author(s):  
Joanna Laurson-Doube ◽  
Nick Rijke ◽  
Anne Helme ◽  
Peer Baneke ◽  
Brenda Banwell ◽  
...  
Keyword(s):  
Multiple Sclerosis ◽  
Clinical Decision Making ◽  
Clinical Decision ◽  
World Health ◽  
World Federation ◽  
Off Label ◽  
Disease Modifying Therapies ◽  
The World ◽  
Disease Modifying ◽  
Health Organization

Background: Off-label disease-modifying therapies (DMTs) for multiple sclerosis (MS) are used in at least 89 countries. There is a need for structured and transparent evidence-based guidelines to support clinical decision-making, pharmaceutical policies and reimbursement decisions for off-label DMTs. Objectives/Results: The authors put forward general principles for the ethical use of off-label DMTs for treating MS and a process to assess existing evidence and develop recommendations for their use. Conclusion: The principles and process are endorsed by the World Federation of Neurology (WFN), American Academy of Neurology (AAN), European Academy of Neurology (EAN), Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS), European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS), Middle-East North Africa Committee for Treatment and Research in Multiple Sclerosis (MENACTRIMS) and Pan-Asian Committee for Treatment and Research in Multiple Sclerosis (PACTRIMS), and we have regularly consulted with the Brain Health Unit, Mental Health and Substance Use Department at the World Health Organization (WHO).

scholarly journals Disease‐Modifying Therapies and Coronavirus Disease 2019 Severity in Multiple Sclerosis

2021 ◽  
Author(s):  
Maria P. Sormani ◽  
Nicola De Rossi ◽  
Irene Schiavetti ◽  
Luca Carmisciano ◽  
Cinzia Cordioli ◽  
...  
Keyword(s):  
Multiple Sclerosis ◽  
Disease Modifying Therapies ◽  
Disease Modifying
Sign in / Sign up

Export Citation Format

Share Document